Skip to main content
Livermore
Livermore
ZHEN

Lunate Holding RSC Ltd

SEC CIK
0002009522
Latest filing
Feb 14, 2025

The latest 13F from Lunate Holding RSC Ltd covers Q4 2024 (filed Feb 14, 2025): 4 long positions worth $210.9M. The top 10 holdings make up 100.0% of the portfolio, and the largest is Revolution Medicines, Inc. (RVMD) at 45.5%. Livermore has 1 filing on Form 13F from this institution, going back to Q4 2024.

What changed in Q4 2024

The five largest holdings this quarter.

Lunate Holding RSC Ltd did not file a 13F for Q3 2024, so this quarter cannot be compared with the previous one.

Top 5 holdings

Share of this quarter's portfolio value

  1. RVMDRevolution Medicines, Inc.
    45.5%$96.1MHistory
  2. BIRKBirkenstock Holding plc
    27.1%$57.2MHistory
  3. LINELineage, Inc.
    16.7%$35.1MHistory
  4. NMRANeumora Therapeutics, Inc.
    10.7%$22.5MHistory

Share of portfolio

Each position's share of portfolio value

  1. RVMD45.5%
  2. BIRK27.1%
  3. LINE16.7%
  4. NMRA10.7%

Metrics

13F metrics for Q4 2024, computed only from the numbers in the filings. Definitions below.

Portfolio value
$210.9M
No prior quarter to compare
Positions
4
No prior quarter to compare
Top 10 concentration
100.0%
Top 10 as share of value
Turnover
–
No prior quarter to compare
Average holding period
1.0 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2024), so positions held before then are understated.

13F filings by quarter

Only Q4 2024 so far.

13F filings of Lunate Holding RSC Ltd by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q4 2024Feb 14, 20254$210.9MRVMDBIRKLINE–SEC

13D and 13G filings

Companies where Lunate Holding RSC Ltd reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

Lunate Holding RSC Ltd does not currently report owning 5% or more of any company.

Latest filings

1 filing on file made by Lunate Holding RSC Ltd or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Lunate Holding RSC Ltd
CompanyFiled (ET)FilerFormStakeChangeEvent dateFiling
LIMENeutron Holdings, Inc.Jul 7, 202612:14 PM ETLunate Capital Ltdand 5 others13G15.30%9.82M sharesNewJun 30, 2026SEC